These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 32792075)
21. Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. Berman AN; Biery DW; Besser SA; Singh A; Shiyovich A; Weber BN; Huck DM; Divakaran S; Hainer J; Kaur G; Blaha MJ; Cannon CP; Plutzky J; Januzzi JL; Booth JN; López JAG; Kent ST; Nasir K; Di Carli MF; Bhatt DL; Blankstein R J Am Coll Cardiol; 2024 Mar; 83(9):873-886. PubMed ID: 38418000 [TBL] [Abstract][Full Text] [Related]
22. [Elevated levels of lipoprotein(a) are present in subjects with early ischemic cardiopathy and with a familial history of ischemic cardiopathy]. Saitta A; Castaldo M; Sardo A; Cinquegrani M; Bonaiuto M; Zema M; Gravina M; Mangano C Minerva Med; 1999; 90(5-6):151-8. PubMed ID: 10780189 [TBL] [Abstract][Full Text] [Related]
23. Family history of atherosclerotic vascular disease is associated with the presence of abdominal aortic aneurysm. Ye Z; Bailey KR; Austin E; Kullo IJ Vasc Med; 2016 Feb; 21(1):41-6. PubMed ID: 26566659 [TBL] [Abstract][Full Text] [Related]
24. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. Longenecker JC; Klag MJ; Marcovina SM; Liu YM; Jaar BG; Powe NR; Fink NE; Levey AS; Coresh J J Am Soc Nephrol; 2005 Jun; 16(6):1794-802. PubMed ID: 15800123 [TBL] [Abstract][Full Text] [Related]
25. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942 [TBL] [Abstract][Full Text] [Related]
26. Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis. Bhatia HS; Rikhi R; Allen TS; Yeang C; Guan W; Garg PK; Tsai MY; Criqui MH; Shapiro MD; Tsimikas S Atherosclerosis; 2023 Sep; 381():117217. PubMed ID: 37607461 [TBL] [Abstract][Full Text] [Related]
27. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146 [TBL] [Abstract][Full Text] [Related]
28. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Agarwala A; Pokharel Y; Saeed A; Sun W; Virani SS; Nambi V; Ndumele C; Shahar E; Heiss G; Boerwinkle E; Konety S; Hoogeveen RC; Ballantyne CM Atherosclerosis; 2017 Jul; 262():131-137. PubMed ID: 28554015 [TBL] [Abstract][Full Text] [Related]
30. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. Ellis KL; Pérez de Isla L; Alonso R; Fuentes F; Watts GF; Mata P J Am Coll Cardiol; 2019 Mar; 73(9):1029-1039. PubMed ID: 30846097 [TBL] [Abstract][Full Text] [Related]
31. Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies. Yano Y; O'Donnell CJ; Kuller L; Kavousi M; Erbel R; Ning H; D'Agostino R; Newman AB; Nasir K; Hofman A; Lehmann N; Dhana K; Blankstein R; Hoffmann U; Möhlenkamp S; Massaro JM; Mahabadi AA; Lima JAC; Ikram MA; Jöckel KH; Franco OH; Liu K; Lloyd-Jones D; Greenland P JAMA Cardiol; 2017 Sep; 2(9):986-994. PubMed ID: 28746709 [TBL] [Abstract][Full Text] [Related]
32. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions. Welsh P; Welsh C; Celis-Morales CA; Brown R; Ho FK; Ferguson LD; Mark PB; Lewsey J; Gray SR; Lyall DM; Gill JMR; Pell JP; de Lemos JA; Willeit P; Sattar N Eur J Prev Cardiol; 2022 Feb; 28(18):1991-2000. PubMed ID: 33624048 [TBL] [Abstract][Full Text] [Related]
33. Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood. Raitakari O; Kartiosuo N; Pahkala K; Hutri-Kähönen N; Bazzano LA; Chen W; Urbina EM; Jacobs DR; Sinaiko A; Steinberger J; Burns T; Daniels SR; Venn A; Woo JG; Dwyer T; Juonala M; Viikari J Circulation; 2023 Jan; 147(1):23-31. PubMed ID: 36440577 [TBL] [Abstract][Full Text] [Related]
34. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. Schaefer EJ; Lamon-Fava S; Jenner JL; McNamara JR; Ordovas JM; Davis CE; Abolafia JM; Lippel K; Levy RI JAMA; 1994 Apr; 271(13):999-1003. PubMed ID: 8139085 [TBL] [Abstract][Full Text] [Related]
35. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. Joshi PH; Khokhar AA; Massaro JM; Lirette ST; Griswold ME; Martin SS; Blaha MJ; Kulkarni KR; Correa A; D'Agostino RB; Jones SR; Toth PP; J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130348 [TBL] [Abstract][Full Text] [Related]
36. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis. Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445 [TBL] [Abstract][Full Text] [Related]
37. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Saeed A; Sun W; Agarwala A; Virani SS; Nambi V; Coresh J; Selvin E; Boerwinkle E; Jones PH; Ballantyne CM; Hoogeveen RC Atherosclerosis; 2019 Mar; 282():52-56. PubMed ID: 30685442 [TBL] [Abstract][Full Text] [Related]
38. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Waldeyer C; Makarova N; Zeller T; Schnabel RB; Brunner FJ; Jørgensen T; Linneberg A; Niiranen T; Salomaa V; Jousilahti P; Yarnell J; Ferrario MM; Veronesi G; Brambilla P; Signorini SG; Iacoviello L; Costanzo S; Giampaoli S; Palmieri L; Meisinger C; Thorand B; Kee F; Koenig W; Ojeda F; Kontto J; Landmesser U; Kuulasmaa K; Blankenberg S Eur Heart J; 2017 Aug; 38(32):2490-2498. PubMed ID: 28449027 [TBL] [Abstract][Full Text] [Related]
39. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank. Welsh P; Al Zabiby A; Byrne H; Benbow HR; Itani T; Farries G; Costa-Scharplatz M; Ferber P; Martin L; Brown R; Fonseca AF; Sattar N Atherosclerosis; 2024 Feb; 389():117437. PubMed ID: 38219651 [TBL] [Abstract][Full Text] [Related]
40. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. Imhof A; Rothenbacher D; Khuseyinova N; Hoffmeister A; Maerz W; Nauck M; Scharnagl H; Koenig W; Brenner H Eur J Cardiovasc Prev Rehabil; 2003 Oct; 10(5):362-70. PubMed ID: 14663298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]